Then we continued to analyze the predictive value of PDIA5 regarding the response of anti-PD-L1 (IMvigor210) and anti-PD-1 (GSE78220) therapy for urothelial cancer and metastatic melanoma cohorts, respectively. This evidence concerns the gene PDCD1 and metastatic melanoma.